Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02205528 · ClinicalTrials.gov registry record · Phase 2
A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT02205528 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 108 participants.
The verdict
NCT02205528, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of the trial is to investigate the efficacy, safety, and tolerability of once-daily subcutaneous (SC) injections of NNC0090-2746 for 12 weeks, as an adjunct to metformin, in participants with T2D.
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Liraglutide
- DRUG NNC0090-2746
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2014-08-18 |
| Est. Completion | 2015-09-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02205528
The ClinicalTrials.gov registry entry for NCT02205528 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02205528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02205528 about?
NCT02205528 is a clinical study titled "A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin". This trial is conducted in the United States of America (USA). The aim of the trial is to investigate the efficacy, safety, and tolerability of once-daily subcutaneous (SC) injections of NNC0090-2746 for 12 weeks, as an adjunct to metformin, in participants with T2D.
What is the current status of trial NCT02205528?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2014-08-18. Estimated completion is 2015-09-15.
What interventions are being tested in trial NCT02205528?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Liraglutide (DRUG), NNC0090-2746 (DRUG).
Who is sponsoring clinical trial NCT02205528?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.